熱門資訊> 正文
Haemonetics在Needham的血管闭合装置竞赛中降级
2025-12-16 03:56
- 美國血液技術(HAE) 0
- 美森(MATX) 0
- 雅培(ABT) 0
- Needham has downgraded Haemonetics (HAE) to hold from buy and removed its price target on concerns over increasing competition.
- Analyst Mike Matson noted that Abbott (ABT) and privately held Cordis have newer venous closure devices.
- Matson said that his checks indicate that Abbott's Perclose ProStyle and Cordis' MYNX Control venous closure device are eating away at sales of Haemonetics VASCADE MVP/MVP XL closure devices in electrophysiology procedures.
- "While HAE is likely to offset the weaker Interventional Technologies growth in FY26 with stronger Plasma and Blood Management Technologies growth, we do not believe that this is sustainable," he wrote, adding, "We expect Interventional Technologies to limit HAE's FY27 revenue and EPS growth and put consensus estimates at risk."
- Haemonetics is down ~5% in Monday trading.
More on Haemonetics
- Haemonetics Is Still Undervalued, Even After The Rally
- Haemonetics Corporation (HAE) Q2 2026 Earnings Call Transcript
- Intuitive Surgical downgraded as Citi previews 2026 in MedTech
- Haemonetics raises 2026 guidance, projects 7%–10% organic growth ex CSL amid strong plasma and hospital performance
- Seeking Alpha’s Quant Rating on Haemonetics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
